

26 June 2023

## Use of Biologic Medicines in Gastroenterology

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following three questions?

1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 35
- Adalimumab Biosimilar 340
- Filgotinib 3
- Golimumab 10
- Infliximab – Remicade
- Infliximab Biosimilar 350 - combined total
- Ozanimod 0
- Tofacitinib 8
- Upadacitinib 6
- Ustekinumab 160
- Vedolizumab
- Vedolizumab Injections ONLY (pre-filled pens or syringes) 180 (inj & inf combined)

2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

- Adalimumab – Humira 2
- Adalimumab Biosimilar 100
- Filgotinib 3
- Golimumab 10
- Infliximab – Remicade
- Infliximab Biosimilar 100 – combined total
- Ozanimod 0
- Tofacitinib 8
- Upadacitinib 4
- Ustekinumab 20
- Vedolizumab
- Vedolizumab Injections ONLY (pre-filled pens or syringes) 130 (inj & inf combined)

26 June 2023

- 3. Does your Trust participate in clinical trials for the treatment of Ulcerative Colitis? If so, please provide the total number of patients taking part in any Ulcerative Colitis study.**

Belfast Trust does take part in clinical trials but there are currently no patients participating in clinical trials for Ulcerative Colitis.